tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY), IVERIC bio (ISEE) and Travere Therapeutics (TVTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on DENTSPLY SIRONA (XRAYResearch Report), IVERIC bio (ISEEResearch Report) and Travere Therapeutics (TVTXResearch Report) with bullish sentiments.

DENTSPLY SIRONA (XRAY)

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on DENTSPLY SIRONA yesterday and set a price target of $65.00. The company’s shares closed last Tuesday at $48.63, close to its 52-week low of $47.40.

According to TipRanks.com, CFA is ranked 0 out of 5 stars with an average return of -11.5% and a 43.0% success rate. CFA covers the Healthcare sector, focusing on stocks such as Patterson Companies, AmerisourceBergen, and Oak Street Health.

DENTSPLY SIRONA has an analyst consensus of Moderate Buy, with a price target consensus of $62.56, which is a 29.0% upside from current levels. In a report issued on March 21, Robert W. Baird also maintained a Buy rating on the stock with a $67.00 price target.

See today’s best-performing stocks on TipRanks >>

IVERIC bio (ISEE)

In a report issued on April 4, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on IVERIC bio, with a price target of $27.00. The company’s shares closed last Tuesday at $18.29, close to its 52-week high of $19.32.

According to TipRanks.com, Kusy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.4% and a 33.3% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Karyopharm Therapeutics, and Apellis Pharmaceuticals.

IVERIC bio has an analyst consensus of Strong Buy, with a price target consensus of $26.25, which is a 38.8% upside from current levels. In a report issued on March 22, Jefferies also initiated coverage with a Buy rating on the stock with a $27.00 price target.

Travere Therapeutics (TVTX)

In a report issued on April 4, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Travere Therapeutics, with a price target of $42.00. The company’s shares closed last Tuesday at $28.32.

According to TipRanks.com, Schwartz is a 1-star analyst with an average return of -1.2% and a 39.7% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Mereo Biopharma Group Plc.

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $44.00, implying a 52.2% upside from current levels. In a report issued on March 30, Piper Sandler also initiated coverage with a Buy rating on the stock with a $42.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed